Professor Morand graduated from Monash University, and trained in rheumatology in Australia and the Royal National Hospital for Rheumatic Diseases, UK. His laboratory research focusses on glucocorticoid-induced proteins in the immune system, and his clinical research on systemic lupus erythematosus. He founded the Asia Pacific Lupus Collaboration, which developed and validated the Lupus Low Disease Activity State (LLDAS) endpoint. He lead the TULIP2 trial of anifrolumab, resulting in regulatory approval of anifrolumab in the US, Japan, Australia, and EU.
Awards include the William E Paul Distinguished Innovator Award and Global Team Science Award of the Lupus Research Alliance, New York, and the Evelyn V Hess Award of the Lupus Foundation of America.
